This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Envarsus XR in African American Renal Transplant Recipients (EXR)

This study is currently recruiting participants.
See Contacts and Locations
Verified November 2016 by Monica Grafals, MD, MPD, Georgetown University
Information provided by (Responsible Party):
Monica Grafals, MD, MPD, Georgetown University Identifier:
First received: November 2, 2016
Last updated: NA
Last verified: November 2016
History: No changes posted

The purpose of this study is to collect data prospectively on African American patients who are taking the immunosuppressant Envarsus post kidney transplant. We are looking to see if African American renal transplant recipients that receive Envarsus will have less tubular injury and calcenurin inhibitor toxicity compared with patients that receive tacrolimus IR.

African americans have the higher rates of CYP3A5 which is associated with the need of higher tacrolimus dose to achieve an adequate level and this many times is associated with signs and symptoms of tacrolimus toxicity such as tremors, headaches and neuropathies.

The retrospective cohort will be African American patients that will be matched by age, gender, type of kidney transplant (living vs deceased) and level of sensitization

Condition Intervention
Renal Transplant Recipients Drug: ENVARSUS®

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Envarsus XR in African American Renal Transplant Recipients

Resource links provided by NLM:

Further study details as provided by Monica Grafals, MD, MPD, Georgetown University:

Primary Outcome Measures:
  • Primary endpoint is to determine the rate of calcineurin inhibitor toxicity as measured by surveillance kidney biopsies. [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Renal function after transplantation [ Time Frame: 1 year ]

Estimated Enrollment: 100
Study Start Date: September 2016
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Open Label
ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. African American race
  2. Adult renal transplant recipients (>18 y/o)
  3. Previous adverse reaction or contraindication to the use of tacrolimus

Exclusion Criteria:

  1. Non African American race
  2. Less than 18 y/o (pediatric patients)
  3. Recipients of liver and small bowel transplants
  4. Adverse reaction to tacrolimus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02956005

United States, District of Columbia
Medstar Georgetown Transplant Institute Recruiting
Washington, District of Columbia, United States, 20005
Contact: Monica Grafals, MD, MPH    202-444-3700      
Sponsors and Collaborators
Georgetown University
  More Information

Responsible Party: Monica Grafals, MD, MPD, Transplant Nephrologist, Georgetown University Identifier: NCT02956005     History of Changes
Other Study ID Numbers: EXR1
Study First Received: November 2, 2016
Last Updated: November 2, 2016

Additional relevant MeSH terms:
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017